SCHEMBL3363029

SCHEMBL3363029

COCCNC(=O)c1ccc(Cl)c(-c2ccc(C=C3SC(=S)NC3=O)o2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.58
POLB P06746 1/20 0.58
KMT2A Q03164 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
HSPD1 P10809 1/20 0.56
HSPE1 P61604 1/20 0.56
INSR P06213 3/20 0.56
IGF1R P08069 3/20 0.56
SLC1A3 P43003 3/20 0.50
PIK3CG P48736 5/20 0.49
PIK3CA P42336 3/20 0.49
PTP4A3 O75365 1/20 0.48
GSK3B P49841 3/20 0.47
MYC P01106 1/20 0.47
HPGD P15428 1/20 0.46
ITGB2 P05107 1/20 0.45
ITGAM P11215 1/20 0.45
GSK3A P49840 2/20 0.45
STAT3 P40763 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12990164 1.00 MEN1 (0.58) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL3363025 1.00 MEN1 (0.58) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL3364742 0.87 MEN1 (0.55) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL3364737 0.87 MEN1 (0.55) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL12990163 0.87 MEN1 (0.55) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL3364825 0.84 HSPD1 (0.58) MEN1POLBKMT2ATDP1HSPD1
SCHEMBL3364820 0.84 HSPD1 (0.58) MEN1POLBKMT2ATDP1HSPD1
SCHEMBL12989659 0.84 HSPD1 (0.58) MEN1POLBKMT2ATDP1HSPD1
SCHEMBL3398902 0.84 PIK3CG (0.68) HSPD1HSPE1INSRIGF1RPIK3CG
SCHEMBL12990182 0.84 PIK3CG (0.68) HSPD1HSPE1INSRIGF1RPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 MEN1 2930/4885POLB 2065/4885KMT2A 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.